Published June 2018 | Version v1
Journal article

IL-21 alleviates allergic asthma in DOCK8-knockout mice

  • 1. Pediatric Research Institute, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Children's Hospital of Chongqing Medical University, Chongqing, 400014 (China)
  • 2. Pediatric Department, Central Hospital of Enshi Autonomous Prefecture, Hubei, 445000 (China)
  • 3. Department of Infectious Diseases, Children's Hospital of Chongqing Medical University, Chongqing, 400014 (China)
  • 4. Department of Dermatology, Children's Hospital of Chongqing Medical University, Chongqing, 400014 (China)
  • 5. Department of Immunology, Children's Hospital of Chongqing Medical University, Chongqing, 400014 (China)
  • 6. Department of Respiratory Diseases, Children's Hospital of Chongqing Medical University, Chongqing, 400014 (China)

Description

Highlights: • DOCK8-KO mice induced by 5 μg of OVA showed markedly allergic asthma. • Nasal administration of rmIL-21 alleviates allergic asthma in KO-OVA mice. • IL-21 administration reduced IgE production in DOCK8-KO mice. Patients with DOCK8 deficiency are at increased susceptibility to develop allergic diseases such as food allergy and asthma. Here, we aimed to analyze the pathogenesis of asthma in DOCK8-deficient patients. In our mouse model, DOCK8-knockout (KO) mice sensitized with low-dose OVA were challenged with 1.5% OVA to induce allergic asthma. As compared to that in WT mice, remarkable airway hyperresponsiveness was observed in KO mice. Increased inflammatory cells and eosinophils infiltrated in airway lumen in KO mice especially around bronchi. KO mice showed higher levels of serum IgE and OVA-specific IgE and significantly elevated IgE-producing B cells in blood and in spleen. Surprisingly, nasal administration with rmIL-21 significantly reduced the airway hyperresponsiveness, inflammatory infiltration, as well as the serum IgE and IgE-producing B cells. DOCK8-knockout mice are susceptible to low-dose OVA induced allergic airway inflammation and airway hyperresponsiveness. Supplementary nasal administration of rmIL-21 alleviates allergic asthma in this mouse model.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.bbrc.2018.04.179

Additional details

Identifiers

DOI
10.1016/j.bbrc.2018.04.179;
PII
S0006291X18309720;

Publishing Information

Journal Title
Biochemical and Biophysical Research Communications
Journal Volume
501
Journal Issue
1
Journal Page Range
p. 92-99
ISSN
0006-291X
CODEN
BBRCA9

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
53054300
Subject category
S60: APPLIED LIFE SCIENCES;
Descriptors DEI
ASTHMA; BRONCHI; EOSINOPHILS; INFLAMMATION; MICE
Descriptors DEC
ANIMALS; BIOLOGICAL MATERIALS; BLOOD; BLOOD CELLS; BODY FLUIDS; DISEASES; LEUKOCYTES; MAMMALS; MATERIALS; PATHOLOGICAL CHANGES; RESPIRATORY SYSTEM; RESPIRATORY SYSTEM DISEASES; RODENTS; SYMPTOMS; VERTEBRATES

Optional Information

Copyright
Copyright (c) 2018 Elsevier Inc. All rights reserved.